Hepatitis B Virus and Human Immunodeficiency Virus Drugs in Pregnancy

StephenW

J Hepatol. 2012 Jul 2. [Epub ahead of print]
Hepatitis B Virus and Human Immunodeficiency Virus Drugs in Pregnancy: Findings from the Antiretroviral Pregnancy Registry.
Brown RS, Verna EC, Pereira MR, Tilson HH, Aguilar C, Leu CS, Buti M, Fagan EA.
Source
Frank Cardile Professor of Medicine, Center for Liver Disease and Transplantation, Columbia University Medical Center, New York 10032.
Abstract
BACKGROUND & AIMS:
Fetal safety of antiviral therapies is important given the long-term treatment of women with chronic hepatitis B (CHB) infection who may become pregnant. We analyzed neonatal safety data from the Antiretroviral Pregnancy Registry (APR), the largest safety database in pregnancy for antivirals used for HIV and
CHB.
METHODS:
Data were extracted from APR cases prospectively enrolled between 1989 and 2011. Primary outcomes were major birth defects rates with exposure to all antivirals, individual classes, and drugs compared to population-based controls. Relevant to CHB, only lamivudine (LAM) and tenofovir disoproxil fumarate (TDF) had sufficient individual data for review (> 200 cases).
RESULTS:
Of 13,711 cases analyzed, the overall birth defect prevalence (2.8%, 95% CI 2.6-3.1%) was comparable to Centers for Disease Control population-based data (2.72%, 2.68-2.76%, p=0.87) and two prospective antiretroviral exposed newborn cohorts (2.8%, 2.5-3.2%, p=0.90 and 1.5%, 1.1-2.0%, p<0.001). The birth defects prevalence between first and second/third trimesters exposure was similar (3.0% vs. 2.7%). No increased risk of major birth defects with LAM or TDF exposure compared to population-based controls was observed. No specific pattern of major birth
defects was observed for individual antivirals or overall.
CONCLUSIONS:
No increased risk of major birth defects including in non-live births was
observed for pregnant women exposed to antivirals relevant to CHB treatment
overall or to LAM or TDF compared to population-based controls. Continued
safety and efficacy reporting on antivirals in pregnancy is essential to
inform patients on their risks and benefits during pregnancy.
Copyright ©
2012. Published by Elsevier B.V.PMID: 22766470 [PubMed - as supplied by
publisher]

StephenW

J肝胆病杂志。 2012年七月2。 [出处提前打印]
乙型肝炎病毒和人类HIV病毒药物在妊娠：从抗逆转录病毒妊娠登记处的结果。
布朗遥感，贝尔纳欧共体，佩雷拉议员，蒂尔森HH，阿吉拉尔Ç，亮氨酸CS，Buti中号，费根的EA。
源
弗兰克Cardile医学教授，肝脏疾病中心和移植，哥伦比亚大学医学中心，纽约10032。
抽象
背景与目的：
抗病毒治疗的胎儿的安全是非常重要的，由于长期治疗慢性乙型肝炎（CHB）感染可能怀孕的妇女。我们分析了新生儿的抗逆转录病毒妊娠登记处（APR）的安全数据，在怀孕的最大的安全数据库，为艾滋病毒的抗病毒药物使用和
慢性乙型肝炎。
方法：
数据被提取从年利率前瞻性与1989年和2011年招收的案件。主要成果为主要出生缺陷率相比，人口控制的所有抗病毒药物，个人类，药物与接触。有关慢性乙型肝炎，拉米夫定（LAM）和富马酸替诺福韦酯（TDF）有足够的个人资料进行审查（200例）。
结果：
对13711例分析，整体出生缺陷发生率（2.8％，95％CI为2.6-3.1％）相比，疾病控制人口为基础的数据中心（2.72％，2.68-2.76％，P = 0.87）和两个未来的抗逆转录病毒暴露新生世代（P = 0.90 2.5-3.2％，2.8％，1.5％，1.1〜2.0％，P <0.001）。出生缺陷患病率之间的第一和第二/第三孕期暴露相似（3.0％比2.7％）。无林或TDF曝光的主要出生缺陷的危险性增加相比，人口为基础的控制进行了观察。没有特定的模式主要出生
缺陷个人抗病毒药物或整体观察。
结论：
不包括非活产婴儿中的重大出生缺陷的风险增加
观察孕妇暴露于慢性乙肝治疗的抗病毒药物有关
相比，整体或LAM或TDF的人口控制。持续
在怀孕期间抗病毒药物的疗效和安全报告是必不可少的
告知患者在怀孕期间对他们的风险和利益。
版权所有©
2012年。出版由Elsevier BVPMID：22766470 [期刊 - 提供出版商]

咬牙硬挺

楼主，进行抗病毒婴儿缺陷率有显著提高吗？似乎没有吧

咬牙硬挺

楼主，进行抗病毒婴儿缺陷率有显著提高吗？似乎没有吧

StephenW

咬牙硬挺 发表于 2012-7-16 06:57
楼主，进行抗病毒婴儿缺陷率有显著提高吗？似乎没有吧

不错, 没有.